Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02592954
Other study ID # BSE2015
Secondary ID
Status Completed
Phase Phase 1
First received October 29, 2015
Last updated December 4, 2017
Start date September 2015
Est. completion date December 2016

Study information

Verified date December 2017
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adult participants will apply a broccoli sprout extract-jojoba oil compound to one arm every night under occlusion for 1 week. Jojoba oil alone will be applied to the other arm. At the end of 1 week, a 6mm punch biopsy will be taken from both arms and analyzed via polymerase chain reaction (PCR) and immunohistochemistry for differences in various skin proteins.


Description:

10 adult volunteers, including African American, Caucasian, male and female participants, will be recruited from parents of patients seen in the pediatric dermatology clinic. Each participant will receive 7ml of broccoli sprout extract (BSE) in jojoba oil, containing 3500nmol of sulforaphane (Please see the preparation of broccoli sprout extract below). 500nmol of sulforaphane will be applied each night. The participants will apply the BSE-jojoba oil mixture over a circle, 3cm in diameter, on the upper arm every night for 7 consecutive nights. The control arm will have only jojoba oil applied. Both arms will be occluded with saran wrap every night. After the seventh night, the volunteers will have a 6mm biopsy taken from each arm (2 total), performed by a dermatology resident. The biopsies will be cleaned with alcohol, numbed with 0.5-1cc of 1% lidocaine with epinephrine, and closed with one 4-0 nylon nonabsorbable suture. The biopsy site will be covered with Vaseline and a bandaid. The area will be kept covered for 24 hours, after which it may be washed with soap and water and then recovered with Vaseline and a bandaid. The suture will be removed 10-14 days after the procedure. From the initial visit through the final visit for suture removal, we expect the duration of the trial to last approximately 1 month. The participants will be told to avoid applying any topical medications or over the counter lotions or creams for the duration of the study and will also be told to wash with Dove soap in the shower. They will also be advised to avoid a diet high in cruciferous plants such as broccoli, mustard, and horseradish. The biopsy results will each be divided in half. One half to be frozen for cryosectioning and immunofluorescence staining and the other half to be used for protein or RNA extraction for molecular assays (real time polymerase chain reaction and/or quantitative polymerase chain reaction for select messenger RNAs and western blotting for select protein antigens). The levels of keratin 1, keratin 5, keratin 10, keratin 14, keratin 16, keratin 17, and Nrf2 will be studied with both immunofluorescence and RNA PCR.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Able to attend 3 visits at the designated times.

Exclusion Criteria:

- Pregnant

- Known allergy to broccoli, lidocaine, or epinephrine

Study Design


Intervention

Drug:
Jojoba oil with broccoli sprout extract
500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
Jojoba oil (placebo)
1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week

Locations

Country Name City State
United States Johns Hopkins Hospital Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunohistochemistry Immunohistochemistry of protein levels of keratin 1, keratin 5, keratin 10, keratin 14, keratin 16, keratin 17, and Nrf2 Within 1 month of skin biopsy
Primary Real time- Polymerase Chain Reaction Real time- Polymerase Chain Reaction of protein levels of keratin 1, keratin 5, keratin 10, keratin 14, keratin 16, keratin 17, and Nrf2 Within 1 month of skin biopsy
Secondary Adverse Events Any adverse events associated with topical application of the drug or placebo During the trial until 2 months after the trial ends
See also
  Status Clinical Trial Phase
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Completed NCT05062070 - Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex Phase 1
Recruiting NCT03016715 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Phase 2
Completed NCT02960997 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Phase 2
Recruiting NCT00936533 - Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Phase 2
Completed NCT03472287 - To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Phase 1
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Not yet recruiting NCT02470689 - Diacerin for the Treatment of Epidermolysis Bullosa Simplex Phase 2
Recruiting NCT03453632 - Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Phase 2/Phase 3
Terminated NCT03154333 - Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) Phase 2
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Completed NCT03389308 - Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex Phase 2